Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors

Abstract Introduction Overexpression of neurotensin (NT) receptors in exocrine pancreatic cancer and other neuroendocrine cancers make them interesting targets for tumor imaging and therapy. Modifications at the cleavage bonds 8–9 and 11–12 led to the synthesis of NT-XII, NT-XIII and NT-XVIII, three new stabilized analogues. (NαHis)Ac was coupled to the N-terminus for labeling with [ 99m Tc]-tricarbonyl. Methods Stability was tested in vitro in human plasma and HT-29 cells. Binding to NT1 receptors and internalization/efflux were analyzed in intact HT-29 cells. Biodistribution studies were performed in nude mice bearing HT-29 xenografts. Results All analogues were very stable in human plasma, with half-lives of 20–21 days. Degradation in HT-29 cells was more rapid ( t 1/2 of 6.5, 5 and 2.5 h for NT-XII, NT-XIII and NT-XVIII, respectively). They also showed high affinity and specificity for NT1 receptors. Bound activity was rapidly internalized at 37°C. The pattern of externalization was different. NT-XII was released more slowly than NT-XIII and NT-XVIII (half of the activity still inside the cells after 24 h). Bigger differences were found in the biodistribution studies. NT-XII showed the highest tumor uptake as well as the best tumor to nontumor ratios. Conclusion The modifications introduced in NT(8–13) increased plasma stability, maintaining unaffected the in vitro binding properties. The best biodistribution corresponded to NT-XII, which shows to be a good candidate for NT1 receptors overexpressing tumors. First clinical trials are ongoing.